TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05913973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pvs230D1-EPA/Matrix-M
Description: Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pvs230D1-EPA/Matrix-M
Description: Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pvs230D1-EPA/Matrix-M
Description: Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.
Study: NCT05043961

Intervention type: PROCEDURE
Intervention: Palisade sacroiliac joint radiofrequency ablation using 3-tined needles
Description: Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion.
Study: NCT05688449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
Study: NCT06205069

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue flossing
Description: While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
Study: NCT06109727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebellar transcranial electrical stimulation
Description: Cerebellar transcranial electrical stimulation - 20 mA - 20 min

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cerebellar transcranial electrical stimulation
Description: Cerebellar transcranial electrical stimulation - 20 mA - 20 min
Study: NCT05972785

Intervention type: DRUG
Intervention: Calcium channel blocker
Description: Drugs with ATC code C08 will be categorised as calcium channel blockers.

Intervention type: DRUG
Intervention: Calcium channel blocker
Description: Drugs with ATC code C08 will be categorised as calcium channel blockers.

Intervention type: DRUG
Intervention: Beta blocker
Description: Drugs with ATC code C07 will be categorised as beta-blockers.

Intervention type: DRUG
Intervention: Beta blocker
Description: Drugs with ATC code C07 will be categorised as beta-blockers.

Intervention type: DRUG
Intervention: Diuretic
Description: Drugs with ATC code C03 will be categorised as diuretics.
Study: NCT05153772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AlphaMedix
Description: 212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
Study: NCT05972785

Intervention type: DRUG
Intervention: Diuretic
Description: Drugs with ATC code C03 will be categorised as diuretics.

Intervention type: DRUG
Intervention: RAS
Description: Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).

Intervention type: DRUG
Intervention: RAS
Description: Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).

Intervention type: DRUG
Intervention: Other AHT
Description: Drugs with ATC code C02 will be categorised as other antihypertensives.

Intervention type: DRUG
Intervention: Other AHT
Description: Drugs with ATC code C02 will be categorised as other antihypertensives.
Study: NCT05143450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Pressure
Description: In the experimental group manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher before the procedure. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated.
Study: NCT04806503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNR844
Description: Ophthalmic solution for topical ocular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNR844
Description: Ophthalmic solution for topical ocular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNR844
Description: Ophthalmic solution for topical ocular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNR844
Description: Ophthalmic solution for topical ocular administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06199778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: 1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers.
Study: NCT05556733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Faecal Microbiota Transplantation
Description: FMT at baseline, week 2, week 4, week 8
Study: NCT05846334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mindfulHeart
Description: 'mindfulHeart' is an interactive, self-guided and patient-oriented mHealth intervention for the reduction of stress in patients with IHD and includes automated feedback via visualization of changes in patient reported outcome measures (PROMs).
Study: NCT05617599

Intervention type: DEVICE
Intervention: SUPRAFLEX CRUZ
Description: Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
Study: NCT04567238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile contingency management
Description: Mobile contingency management is a mobile-phone based behavioral therapy that provides positive reinforcement (i.e., money) for abstinence that is highly effective at reducing substance use.
Study: NCT05392946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given PO
Study: NCT06531876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreem 3S recording
Description: Subjects in both Arms A and B will undergo at-home recording with the Dreem 3S EEG Headband to assess sleep. Subjects will undergo in-lab polysomnography and multiple sleep latency testing while also wearing the Dreem 3S EEG headband system. Arm B participants will be asked to withdraw from some or all of their Narcolepsy related medication therapy for roughly 19 days in order to assess the ability of the Dreem Headband System in characterizing sleep disturbances related to Narcolepsy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreem 3S recording
Description: Subjects in both Arms A and B will undergo at-home recording with the Dreem 3S EEG Headband to assess sleep. Subjects will undergo in-lab polysomnography and multiple sleep latency testing while also wearing the Dreem 3S EEG headband system. Arm B participants will be asked to withdraw from some or all of their Narcolepsy related medication therapy for roughly 19 days in order to assess the ability of the Dreem Headband System in characterizing sleep disturbances related to Narcolepsy.
Study: NCT06210945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg CM-101
Description: 10 mg/kg CM-101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05972785

Intervention type: DRUG
Intervention: None AHT
Description: None AHT
Study: NCT06324461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75mg subcutaneous injection
Description: Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 7 to 14 days prior to surgery
Study: NCT04994613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory adaptive environment
Description: A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
Study: NCT05309291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 Dialyzer
Description: Dialysis performed in HD mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX 800 Dialyzer
Description: Dialysis performed in HDF mode.
Study: NCT06644599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wireless monitoring
Description: The monitoring wireless system will continuously monitor the heart rate, oxygen saturation (SpO2), respiratory rate, and blood pressure and in selected patients electrocardiography (ECG).
Study: NCT06512558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional MRI with gadolinium injection and 3D camera imaging
Description: The study includes an additional MRI with gadolinium injection, performed in addition to standard practice. In addition, 3D camera images will be acquired at the time of surgery.
Study: NCT06373120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorVad
Description: The CorVad percutaneous ventricular assist system device is a microaxial rotary blood pump that expels blood from the left ventricle into the ascending aorta, thus unloading the left ventricle. The CorVad system device can be introduced through a femoral percutaneous approach (14Fr) and can deliver an output of up to 4-6 L/min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VA-ECMO
Description: Veno-arterial extracorporeal Membrane Oxygenation (VA-ECMO) is a device originally created to replace heart and lung function. Venous deoxygenated blood is mechanically suctioned from a large central vein through a venous cannula by a centrifugal pump. It is then oxygenated, warmed, and restored into systemic circulation through an arterial cannula.
Study: NCT05019079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
Study: NCT05317481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BE-SMART-DR
Description: Therapy that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducational control comparator condition (CC)
Description: Structured sessions, matched for BE-SMART-DR session number and time, that will emphasize established strategies to manage health and well being
Study: NCT06589128

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin Oral Capsule
Description: Once daily supplementation of oral astaxanthin capsule for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily supplementation of olive oil capsule for 24 weeks
Study: NCT04950439

Intervention type: OTHER
Group type: OTHER
Intervention: Collect blood sample
Description: A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
Study: NCT06609096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual counseling based on the PLISSIT model
Description: Four sessions of sexual counseling based on the PLISSIT model will be provided. The intervention consisted of four consecutive sessions, with one session per week. Each session is 30 minutes on average.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual counseling based on the BETTER model
Description: A total of four sessions of sexual counseling based on the BETTER model will be provided. The intervention consists of four consecutive sessions, one session per week. Each session is 30 minutes on average.
Study: NCT06456164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Cervical Ripening Balloon
Description: The Cook Cervical Ripening Balloon is a double-balloon catheter designed to mechanically ripen the cervix prior to labor induction when the cervix is unfavorable for induction.
Study: NCT06589934

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Precise Image
Description: Image reconstruction software
Study: NCT06675292

Intervention type: OTHER
Intervention: Survey-based study
Description: The demographic information of individuals with tension-type headaches, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test-6, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
Study: NCT06502119

Intervention type: OTHER
Intervention: Designed Questionnaire
Description: Participants in this study, comprised solely of obstetricians and gynecologists practicing in Egypt, will complete a self-administered questionnaire designed to assess their knowledge, attitudes, and practices related to operative vaginal birth. The questionnaire includes four sections: the first gathers demographic data such as name, gender, and years of experience in childbirth care; the second focuses on participants' practices regarding the frequency and types of operative vaginal birth used (forceps, ventouse) and reasons for their use; the third evaluates knowledge of outcomes associated with operative vaginal birth through multiple-choice questions; and the fourth explores attitudes towards operative vaginal birth, including opinions on hospital rates and policy appropriateness. Completion and return of the questionnaire, which takes approximately 5 to 10 minutes, will be considered as consent to participate in the study.
Study: NCT05274919

Intervention type: DEVICE
Intervention: Philips Achieva 7T MRI
Description: Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.

Intervention type: DEVICE
Intervention: Philips Achieva 7T MRI
Description: Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
Study: NCT05952869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05274919

Intervention type: DEVICE
Intervention: X-ray (optional)
Description: Optional X-ray scan to assess the safety for undergoing an MR examination.
Study: NCT05896839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT05274919

Intervention type: DEVICE
Intervention: X-ray (optional)
Description: Optional X-ray scan to assess the safety for undergoing an MR examination.

Intervention type: DEVICE
Intervention: X-ray (optional)
Description: Optional X-ray scan to assess the safety for undergoing an MR examination.

Intervention type: COMBINATION_PRODUCT
Intervention: Additional contrast injection
Description: Contrast agent administration for the additional 7T scan (optional).

Intervention type: COMBINATION_PRODUCT
Intervention: Additional contrast injection
Description: Contrast agent administration for the additional 7T scan (optional).

Intervention type: OTHER
Intervention: Question list
Description: Questionnaire for contra-indications for an MR examination.

Intervention type: OTHER
Intervention: Question list
Description: Questionnaire for contra-indications for an MR examination.

Intervention type: OTHER
Intervention: Question list
Description: Questionnaire for contra-indications for an MR examination.
Study: NCT06673498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lusutrombopag combined with recombinant human thrombopoietin
Description: After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days
Study: NCT06675760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intervention group
Description: The intervention group received training through a mobile augmented reality application in the laboratory.
Study: NCT05788991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dequalinium Chloride
Description: Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: Metronidazole oral tablets (500 mg) taken twice a day for 7 days
Study: NCT06607770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karelizumab+Apatinib
Description: Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
Study: NCT05925400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality during Embryo Transfer
Description: Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 10-15 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
Study: NCT06750549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENGAGE-HF Mobile Application
Description: The mobile app aids ambulatory heart failure monitoring and patient engagement through several features:~Physiologic Monitoring: Daily tracking of blood pressure, weight, and heart rate using Bluetooth devices. Data is shown in graphical and tabular formats.~Health Status Assessment: Biweekly KCCQ-12 surveys and dizziness questions provide scores (0-100), helping visualize therapy benefits and medication adherence, and reducing clinician inertia.~Medication Checklist: Lists current medications and target doses for common heart failure therapies, encouraging adherence and optimization, with alerts for potential improvements.~Education: Animated videos from heart failure experts and societies explain medications, monitoring rationale, app features, and interpretation of data.~The app enhances heart failure management via consistent monitoring, assessment, medication adherence, and educational content.
Study: NCT05896839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Biopsy
Description: Undergo kidney biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT05575063

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Healon Endocoat
Description: Ophthalmic Viscoelastic device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Healon Endocoat
Description: Ophthalmic Viscoelastic device
Study: NCT06489431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: Aminoglycoside antibiotic irrigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Antibacterial known to inhibit DNA-dependent RNA polymerase
Study: NCT05301764

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LVGN6051 and Anlotinib
Description: LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area \< 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area \< 1.5m2.~One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week.
Study: NCT06499350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FC084CSA+Tislelizumab combination (dose escalation)
Description: Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D of FC084CSA+Tislelizumab combination (dose expansion)
Description: RP2D of FC084CSA+fixed dose Tislelizumab combination therapy
Study: NCT06116175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60 degree thermal radiofequency of tennis elbow
Description: under strict aseptic technique ultrasound guided TRF of lateral epicondylitis advanced for 5 mm active tip canula